Last reviewed · How we verify

Factor VII deficiency — Treatment Landscape & Competitive Intelligence

Factor VII deficiency (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Factor VII deficiency, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Eptacog Alfa EPTACOG ALFA (ACTIVATED) Novo Nordisk 1996-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Novo Nordisk · 1 drug in Factor VII deficiency

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Factor VII deficiency:

Cite this brief

Drug Landscape (2026). Factor VII deficiency — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/factor-vii-deficiency. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing